References
- Dondorp AM, Nosten F, Yi P et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med.361, 455–467 (2009).
- Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in Western Cambodia. N. Engl. J. Med.359, 2619–2620 (2008).
- Dahlstrom S, Ferreira PE, Veiga MI et al.Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J. Infect. Dis.200, 1456–1464 (2009).
- Sisowath C, Petersen I, Veiga MI et al.In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Infect. Dis.199, 750–757 (2009).
- Sisowath C, Stromberg J, Martensson A et al.In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J. Infect. Dis.191, 1014–1017 (2005).
- Staines HM, Derbyshire ET, Slavic K, Tattersall A, Vial H, Krishna S. Exploiting the therapeutic potential of Plasmodium falciparum solute transporters. Trends Parasitol.26, 284–296 (2010).
- Slavic K, Straschil U, Reininger L et al. Life cycle studies of the hexose transporter of Plasmodium species and genetic validation of their essentiality. Mol. Microbiol.75, 1402–1413 (2010).
- Rottmann M, Mcnamara C, Yeung BK et al. Spiroindolones, a potent compound class for the treatment of malaria. Science329, 1175–1180 (2010).
- Hill AV, Reyes-Sandoval A, O’Hara G et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin.6, 78–83 (2010).
- Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet372, 1881–1893 (2008).
- Draper SJ, Goodman AL, Biswas S et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe5, 95–105 (2009).
- Draper SJ, Moore AC, Goodman AL et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med.14, 819–821 (2008).
- Reyes-Sandoval A, Berthoud T, Alder N et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect. Immun.78, 145–153 (2010).
- Douglas AD, De Cassan SC, Dicks MD, Gilbert SC, Hill AV, Draper SJ. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine28, 7167–7178 (2010).
- Berriman M, Haas BJ, Loverde PT et al. The genome of the blood fluke Schistosoma mansoni. Nature460, 352–358 (2009).
- Norton AJ, Gower CM, Lamberton PH et al. Genetic consequences of mass human chemotherapy for Schistosoma mansoni: population structure pre- and post-praziquantel treatment in Tanzania. Am. J. Trop. Med. Hyg.83, 951–957 (2010).
- Keiser J, N’guessan NA, Adoubryn KD et al. Efficacy and safety of mefloquine, artesunate, mefloquine–artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin. Infect. Dis.50, 1205–1213 (2010).
Website
- World Health Organization www.who.int.